Heart failure & cardiomyopathies
Successful Conservative Management of Left Ventricular Assist Device Candidates
Authors' conclusion
Notwithstanding the small size of our cohort, our results suggest that LVAD implantation could be safely deferred in the majority of LVAD candidates.
Study context
- Population
- Consecutive patients with advanced heart failure (HF) fulfilling criteria for left ventricular assist device (LVAD) implantation, managed with aggressive conservative therapymean age 63 ± 10.8 years
- Participants
- 28 patients
- Outcome
- Long-term clinical stabilization with aggressive conservative therapy
Methodological detailssingle-centre, consecutive patients, Initial therapy: inotropes, thiamine, beta-blockers, digoxin, spironolactone, hydralazine and nitrates, then novel HF therapies; coronary revascularization and CRT when indicated
- Single-centre
- Consecutive patients
- Initial therapy: inotropes, thiamine, beta-blockers, digoxin, spironolactone, hydralazine and nitrates, then novel HF therapies; coronary revascularization and CRT when indicated
Main finding
As reported in the abstract
Clinical stabilization achieved and maintained · median follow-up 20 months, range 9-38 months
Clinical stabilization achieved and maintained (patients)
21
Deaths
3
Ultimately required LVAD implantation
4
Observational data: associations, not effects.
Further findings
Haemodynamic and functional measures, baseline vs follow-up
- Cardiac index increased (L/min/m²)
- 2.05 (1.73-2.28) to 2.88 (2.63-3.55)
- LV end-diastolic diameter decreased (mm)
- 65.5 (62.4-66) to 58.3 (53.8-62.5)
- Maximal oxygen consumption increased (mL/kg/min)
- 10.1 (9.2-11.3) to 16.1 (15.3-19)
Original publication
Successful Conservative Management of Left Ventricular Assist Device Candidates. ESC Heart Fail. Published 15 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →